MLYS Stock: Earnings, Dividends & Analyst Estimates

Company Overview:

Market Cap: $2.07B

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $22.30 - $47.65

3.6 Year MLYS Performance Metrics:

Total Return (with DRIP): 32.8% (8.19% CAGR)

Total Return (no DRIP): 32.8% (8.19% CAGR)

Share Price: 32.8% (8.19% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $13,275

Total Return $ (with DRIP): $3,275

MLYS Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

MLYS Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

Pro

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for MLYS

Based on past 3.6-year performance, here are MLYS growth metrics:

Share price CAGR of +8.19%
Dividend CAGR of +0%

Using MLYS CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	MLYS (DRIP)	MLYS - No DRIP
Current Price	$24.48	$24.48
Start Shares	408.50	408.50
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	408.50	408.50
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$24.48	$24.48
Total Dividends	$0	$0
Final Value	$10,000	$10,000

Estimated Future Value + Dividends - MLYS

NOTE: Above numbers are our estimate based on MLYS's Dividend and Price CAGR over past 3.6 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

Pro

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Try it free for 7 days

You save $125.40 (55%)

Company Info

Mineralys Therapeutics, Inc. (MLYS) had its IPO on , and is traded on NASDAQ stock exchange.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for diseases driven by dysregulated aldosterone. Its lead product candidate, lorundrostat, is an orally administered, highly selective aldosterone synthase inhibitor being studied for cardiorenal conditions such as hypertension, chronic kidney disease, and obstructive sleep apnea. Mineralys Therapeutics concentrates on the treatment of hypertension and related comorbidities, aiming to address patients who do not respond adequately to existing therapies. The company operates as a development-stage drugmaker with a pipeline centered on aldosterone-targeted treatment, combining clinical research, regulatory activity, and outsourced manufacturing and trial operations. Based in Radnor, Pennsylvania, Mineralys Therapeutics plays a specialized role in the biopharmaceutical market by advancing therapies for cardiometabolic and renal diseases with a focus on precision targeting of hormone-driven pathways.

MLYS website: https://mineralystx.com